GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Quality Rank

Evotec SE (WBO:EVT) Quality Rank


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Evotec SE Quality Rank Related Terms

Thank you for viewing the detailed overview of Evotec SE's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Quality Rank
Comparable Companies
GNTY MCBS CARE UNTN ABCB SSB UBSI FRBA QNTO HIFS ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Website
https://www.evotec.com
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.